Table 2.

Adjusted ORs and 95% CIs of the association of breast cancer case-control status and genotype main effects

GenotypeEuropean Americans (%)
African Americans (%)
ControlsCasesAdjusted OR* (95% CI)ControlsCasesAdjusted OR* (95% CI)
No COMT Met512 (78%)377 (77%)1372 (91%)149 (87%)1
Any COMT Met147 (22%)115 (23%)1.07 (0.81-1.44)39 (9%)23 (13%)1.41 (0.80-2.48)
No CYP1A1*2C682 (94%)487 (91%)1404 (90%)187 (94%)1
Any CYP1A1*2C40 (6%)50 (9%)1.71 (1.09-2.67)43 (10%)11 (6%)0.62 (0.31-1.25)
No CYP1A2*1F57 (9%)45 (9%)167 (16%)32 (19%)1
Any CYP1A2*1F611 (91%)451 (91%)1.03 (0.67-1.57)340 (84%)137 (81%)0.86 (0.53-1.38)
No CYP1B1*4494 (73%)343 (69%)1402 (93%)164 (89%)1
Any CYP1B1*4186 (27%)155 (31%)1.13 (0.87-1.47)32 (7%)20 (11%)1.48 (0.80-2.72)
No CYP3A4*1B650 (92%)464 (90%)196 (22%)43 (24%)1
Any CYP3A4*1B57 (8%)54 (10%)1.35 (0.90-2.02)332 (78%)137 (76%)0.94 (0.62-1.45)
No SULT1A1*2297 (53%)199 (47%)1193 (56%)85 (59%)1
Any SULT1A1*2259 (47%)226 (53%)1.24 (0.96-1.61)153 (44%)59 (41%)0.87 (0.58-1.32)
No SULT1E1 A613 (86%)432 (83%)1293 (68%)130 (71%)1
Any SULT1E1 A97 (14%)89 (17%)1.30 (0.94-1.79)141 (32%)53 (29%)0.89 (0.60-1.31)
  • * Estimated from conditional logistic regression matched on age, and adjusted for the following variables: age at menarche, number of full-term pregnancies, age at menopause, duration of oral contraceptive use, body mass index, and existence of first-degree relative with breast cancer.